Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials.
The company has promoted Marc Evanchik to the position of Chief Scientific Officer to oversee clinical development, research, and scientific strategy. Concurrently, Brittany de Temple has joined as the Senior Vice President of Development Operations to enhance preparedness for expanded clinical operations. These key appointments come amidst the company's progress towards the upcoming launch of global initiatives.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments